Although these compounds require further characterization and optimization, they provide a foundation for developing selective MBOAT7 inhibitors as therapeutic agents for aggressive cancers with MBOAT7 dependency, where their use may be valuable despite potential adverse effects such as causing transient fatty liver. The gene discussed is MBOAT7; the disease is medical procedure.